These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 9498718)

  • 1. 2-chlorodeoxyadenosine administration to patients with the myeloid blast phase of chronic myelogenous leukemia.
    Gollard R; Miller WE; Piro LD; Saven A
    Leuk Lymphoma; 1997 Dec; 28(1-2):183-5. PubMed ID: 9498718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete hematologic remissions in chronic-phase, Philadelphia-chromosome-positive, chronic myelogenous leukemia after 2-chlorodeoxyadenosine.
    Saven A; Piro LD; Lemon RH; Figueroa ML; Kosty M; Ellison DJ; Beutler E
    Cancer; 1994 Jun; 73(12):2953-63. PubMed ID: 7911068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cladribine combined with mitoxantrone in the treatment of blastic phase of chronic myeloid leukemia.
    Robak T; Góra-Tybor J
    Neoplasma; 2001; 48(3):203-7. PubMed ID: 11583290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose cladribine therapy for chronic myelogenous leukemia in the accelerated or blast phase.
    Dann EJ; Anastasi J; Larson RA
    J Clin Oncol; 1998 Apr; 16(4):1498-504. PubMed ID: 9552058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib.
    Koh Y; Kim I; Yoon SS; Kim BK; Kim DY; Lee JH; Lee KH; Park E; Kim HJ; Sohn SK; Joo YD; Kim SJ; Chung J; Shin HJ; Kim SH; Kim CS; Song HS; Kim MK; Hyun MS; Ahn JS; Jung CW; Park S;
    Ann Hematol; 2010 Jul; 89(7):725-31. PubMed ID: 20179930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.
    Thota NK; Gundeti S; Linga VG; Coca P; Tara RP;
    Indian J Cancer; 2014; 51(1):5-9. PubMed ID: 24947087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of carboplatin in blast crisis of chronic myeloid leukemia: Eastern Cooperative Oncology Group Study E1992.
    Dutcher JP; Lee S; Paietta E; Bennett JM; Stewart JA; Wiernik PH
    Leukemia; 1998 Jul; 12(7):1037-40. PubMed ID: 9665187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
    Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
    Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Very long survival in complete cytogenetic remission in an adolescent with lymphoid blast crisis of chronic myeloid leukemia after treatment with intensive ALL-directed chemotherapy combined with continuous imatinib.
    Maschan A; Novichkova G; Miakova N; Persiantseva M
    Pediatr Blood Cancer; 2016 Dec; 63(12):2243-2245. PubMed ID: 27434016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Combination of imatinib and anagrelide in treatment of chronic myeloid leukemia in blastic phase].
    Voglová J; Maisnar V; Beránek M; Chrobák L
    Vnitr Lek; 2006 Sep; 52(9):819-22. PubMed ID: 17091608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
    Cohen MH; Johnson JR; Pazdur R
    Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Purine nucleoside analogues in the treatment of myleoid leukemias.
    Robak T
    Leuk Lymphoma; 2003 Mar; 44(3):391-409. PubMed ID: 12688309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promyelocytic blast crisis of chronic myeloid leukemia during imatinib treatment.
    Chung HJ; Chi HS; Cho YU; Park CJ; Seo EJ; Kim KH; Lee JH
    Ann Clin Lab Sci; 2008; 38(3):283-6. PubMed ID: 18715859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Megakaryocytic blast crisis as first presentation of chronic myeloid leukemia.
    Campiotti L; Grandi AM; Biotti MG; Ultori C; Solbiati F; Codari R; Venco A
    Am J Hematol; 2007 Mar; 82(3):231-3. PubMed ID: 17022045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral idarubicin in the treatment of acute myelogenous leukaemia and the blast phase of chronic myeloid leukaemia.
    Malik ST; Tucker J; Rohatiner AZ; Brace W; Lister TA
    Hematol Oncol; 1989; 7(6):423-7. PubMed ID: 2807180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
    Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
    Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Reversion to chronic phase of chronic myelogenous leukemia in blast crisis with small-dose daunorubicin and oral prednisolone].
    Kuyama J; Take H
    Rinsho Ketsueki; 1995 Dec; 36(12):1353-8. PubMed ID: 8587171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stem cell regulation and the development of blast crisis in chronic myeloid leukemia: Implications for the outcome of Imatinib treatment and discontinuation.
    Wodarz D
    Med Hypotheses; 2008; 70(1):128-36. PubMed ID: 17566666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.